Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serhat Sekmek

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Anti-Cancer Drugs|January 3, 2025
A rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinibİsmet Seven, Fahriye Tuğba Köş, Hayriye Tatli Doğan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 19, 2026
Prognostic ımpact of the modified Ryan tumor regression score in gastric and GEJ adenocarcinomas treated with neoadjuvant FLOT regimenMehmet Akif Parlar, Burak Bilgin, Bülent Yalçın, et al.
Oncology Research and Treatment|December 1, 2024
Prognostic Significance of HER2 Positivity in Endometrium CancerSerhat Sekmek, Dogan Bayram, Irfan Karahan, et al.
Diagnostics (Basel, Switzerland)|October 29, 2025
Clinicopathologic Disease Characteristics and Their Association with Adjuvant Chemotherapy Outcomes in Pulmonary Large-Cell Carcinoma Patients with or Without Neuroendocrine FeaturesDoğan Bayram, Oznur Bal, Efe Cem Erdat, et al.
Current Medical Research and Opinion|June 10, 2024
Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group StudyKadriye Bir Yücel, Muzaffer Uğraklı, Serhat Sekmek, et al.
Oncology Research and Treatment|April 10, 2025
The Effect of Positron Emission Tomography-Computed Tomography Parameters on Pathological Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant TreatmentSerhat Sekmek, Ozkan Bayrakcı, Mehmet Akif Karacan, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
A New Prognostic Indicator for Biliary Tract Cancers: The ABIC ScoreDoğan Bayram, Öznur Bal, Kemal Karaman, et al.
Clinical Medicine Insights. Oncology|October 24, 2025
Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal MesotheliomaDoğan Bayram, Safa Can Efil, Serap Türk, et al.
Indian Journal of Thoracic and Cardiovascular Surgery|October 17, 2024
Clinical features and prognostic factors in thymoma and thymic carcinomaDoğan Bayram, Serhat Sekmek, Mehmet Kayaalp, et al.
Journal of Hepatocellular Carcinoma|December 25, 2025
The Combined ALBI-FIB-4 Score for Prognostic Stratification in Hepatocellular Carcinoma: A Single Center Retrospective StudyDoğan Bayram, Efe Cem Erdat, Sema Nur Özsan Çelebi, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Anti-Cancer Drugs|January 3, 2025
A rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinibİsmet Seven, Fahriye Tuğba Köş, Hayriye Tatli Doğan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 19, 2026
Prognostic ımpact of the modified Ryan tumor regression score in gastric and GEJ adenocarcinomas treated with neoadjuvant FLOT regimenMehmet Akif Parlar, Burak Bilgin, Bülent Yalçın, et al.
Oncology Research and Treatment|December 1, 2024
Prognostic Significance of HER2 Positivity in Endometrium CancerSerhat Sekmek, Dogan Bayram, Irfan Karahan, et al.
Diagnostics (Basel, Switzerland)|October 29, 2025
Clinicopathologic Disease Characteristics and Their Association with Adjuvant Chemotherapy Outcomes in Pulmonary Large-Cell Carcinoma Patients with or Without Neuroendocrine FeaturesDoğan Bayram, Oznur Bal, Efe Cem Erdat, et al.
Current Medical Research and Opinion|June 10, 2024
Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group StudyKadriye Bir Yücel, Muzaffer Uğraklı, Serhat Sekmek, et al.
Oncology Research and Treatment|April 10, 2025
The Effect of Positron Emission Tomography-Computed Tomography Parameters on Pathological Response in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant TreatmentSerhat Sekmek, Ozkan Bayrakcı, Mehmet Akif Karacan, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
A New Prognostic Indicator for Biliary Tract Cancers: The ABIC ScoreDoğan Bayram, Öznur Bal, Kemal Karaman, et al.
Clinical Medicine Insights. Oncology|October 24, 2025
Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal MesotheliomaDoğan Bayram, Safa Can Efil, Serap Türk, et al.
Indian Journal of Thoracic and Cardiovascular Surgery|October 17, 2024
Clinical features and prognostic factors in thymoma and thymic carcinomaDoğan Bayram, Serhat Sekmek, Mehmet Kayaalp, et al.
Journal of Hepatocellular Carcinoma|December 25, 2025
The Combined ALBI-FIB-4 Score for Prognostic Stratification in Hepatocellular Carcinoma: A Single Center Retrospective StudyDoğan Bayram, Efe Cem Erdat, Sema Nur Özsan Çelebi, et al.
Pageof 4